A 50-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Subjects With Acute Manic or Mixed Episodes Associated With Bipolar I Disorder

Trial Profile

A 50-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Subjects With Acute Manic or Mixed Episodes Associated With Bipolar I Disorder

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Oct 2016

At a glance

  • Drugs Asenapine (Primary)
  • Indications Bipolar I disorders
  • Focus Adverse reactions
  • Acronyms ADDRESS-98
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 08 Oct 2016 New trial record
    • 08 Jul 2013 Planned end date changed from Aug 2014 to Sep 2014
    • 19 Mar 2012 Planned end date changed from Sep 2013 to Aug 2013
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top